Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Apple Turns 50: From Garage Startup to AI Crossroads 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Britain Courts Anthropic Amid US Defense Department Dispute 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
PHILADELPHIA and OXFORD, United Kingdom, July 31, 2017 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer will announce financial results for the quarter ended June 30, 2017 before the open of the U.S. markets on Thursday, August 3, 2017.
The Company will not be hosting a live teleconference this quarter. The press release will be available in the investor section of Adaptimmune’s corporate website at www.adaptimmune.com.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 10, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contacts Investor Relations Juli P. Miller, Ph.D. T: (215) 825-9310 E: [email protected] Media Relations Margaret Henry T: +44 (0)1235 430036 Cell: +44 (0)7710 304249 E: [email protected]
